"We're not doing 30 bets a year": Vijay Pande on betting small after running $4 billion at a16z

TL;DR

Summary:
- The article profiles Vijay Pande, a general partner at Andreessen Horowitz (a16z), focusing on his disciplined investment strategy in the biotech and life sciences sectors.
- It highlights the shift in venture capital philosophy from "spray and pray" models toward a more concentrated, high-conviction approach to funding deep-tech and scientific innovation.

Like summarized versions? Support us on Patreon!